文献速递免疫规划传染病防控与疫情报告

健康成人接种BNT162b2疫苗后6个月内抗SARS-CoV-2抗体滴度动力学:两种免疫分析法的前瞻性队列研究(日本)

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
PubMed 文献 · Vaccine · 2022-08-15

本研究为日本前瞻性队列研究,纳入385名未感染SARS-CoV-2的健康成人(多为医务人员,20-64岁),于2021年3月至5月接种两剂BNT162b2疫苗,用Architect和Elecsys两种免疫分析法检测抗RBD抗体。结果显示两种分析法测得的抗体动力学不同,GMT在老年组显著较低,作者提示单一种免疫分析法的结果需谨慎解读。

要点

  • 接种两剂BNT162b2后抗体应答充分,但随年龄增长GMT显著降低(P<0.01)。
  • Architect法GMT在第二剂后4周为7007 AU/mL,6个月降至1030 AU/mL。
  • Elecsys法GMT在第二剂后4周为928 U/mL,6个月降至659 U/mL。

核心结论

  • 两剂BNT162b2疫苗可诱导充分的抗RBD抗体应答,且随年龄变化。
  • 两种免疫分析法显示不同的抗体动力学,单一种免疫分析法的结果应谨慎解读。

研究设计与样本

  • 前瞻性队列研究,纳入385名未感染SARS-CoV-2的健康成人(多为医务人员),年龄20-64岁,于2021年3月至5月接种两剂BNT162b2疫苗。
  • 于首次接种前(S0)、第二次接种前(S1)、第二次接种后4周(S2)和第二次接种后6个月(S3)采集血样。
  • 使用Architect SARS-CoV-2 IgG II Quant(Abbott Laboratory)和Elecsys anti-SARS-CoV-2 S(Roche Diagnostics)两种免疫分析法检测抗RBD抗体。

主要发现

  • Architect法(AU/mL)的GMT在S0、S1、S2、S3分别为7.5、693、7007、1030。
  • Elecsys法(U/mL)的GMT在S0、S1、S2、S3分别为0.40、24、928、659。
  • GMT比值(S3/S2)在Architect法为0.15,在Elecsys法为0.71。
  • 两种分析法测得的抗体滴度在接种后所有时间点强相关(Spearman相关系数0.74至0.86,所有P<0.01)。
  • 接种后老年组GMT显著较低(P<0.01),性别间无显著差异。

关键数值与推荐

  • 血清保护阈值:Architect法≥5458 AU/mL,Elecsys法≥753 U/mL。
  • GMT比值(S3/S2):Architect法0.15,Elecsys法0.71。
  • 两种分析法相关性:Spearman相关系数0.74至0.86,所有P<0.01。

临床怎么用

  • 作者认为,由于两种免疫分析法显示不同的动力学,单一种免疫分析法的结果应谨慎解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although several assays are used to measure anti-receptor-binding domain (RBD) antibodies induced after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, the assays are not fully comparable in practice. This study evaluated the immunogenicity of the BNT162b2 mRNA vaccine in healthy adults using two immunoassays. METHODS: This prospective cohort study included SARS-CoV-2-naïve adults, predominantly healthcare workers, aged 20-64 years, who received two BNT162b2 vaccine doses between March and May 2021. Blood samples were collected before the first vaccination (S0), before the second vaccination (S1), 4 weeks after the second vaccination (S2), and 6 months after the second vaccination (S3). anti-RBD antibodies were measured using the Architect SARS-CoV-2 IgG II Quant (Abbott Laboratory) and Elecsys anti-SARS-CoV-2 S (Roche Diagnostics) assays. RESULTS: Among the 385 participants, the geometric mean antibody titers (GMTs) on the Architect assay (AU/mL) were 7.5, 693, 7007, and 1030 for S0, S1, S2, and S3, respectively. The corresponding GMTs on the Elecsys assay (U/mL) were 0.40, 24, 928, and 659, respectively. The GMT ratio (S3/S2) was 0.15 on the Architect and 0.71 on the Elecsys assay. The correlation between antibody titers measured with the two assays were strong at all time points after vaccination (Spearman's correlation coefficient: 0.74 to 0.86, P < 0.01 for all). GMT was significantly lower in the older age group after vaccination (P < 0.01), with no significant differences according to sex. Seroprotection (≥5458 AU/mL on the Architect assay and ≥ 753 U/mL on the Elecsys) at each time point was 0 %, 1 %, 67 %, and 1 % on the Architect assay and 0 %, 1 %, 62 %, and 43 % on the Elecsys, respectively. CONCLUSIONS: Two BNT162b2 vaccine doses resulted in adequate anti-RBD antibody response, which varied by age. As the two assays showed different kinetics, the results of single immunoassays should be interpreted with caution.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Matsuura T, Fukushima W, Nakagama Y, et al. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Vaccine. 2022. PMID: 36028457. doi:10.1016/j.vaccine.2022.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。